SMARCA4 and lung adenocarcinoma: For the lung adenocarcinoma (LUAD) patients, the mutational rate in DACH1 was higher in the higher-score individuals, while CDKN2A and SMARCA4 were higher in the lower-score individuals (Figure S7B).